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ABSTRACT 
USE OF FUNCTIONALIZED GOLD NANOPARTICLES TO EFFICIENTLY 
EXTRACT AND CONCENTRATE PEPTIDES FOR MALDI-TOF-MS DETECTION 
 
MAY 2007 
 
BENJAMIN PAPA KWESI NII YANKOS VANDERPUIJE, B.Sc, KWAME  
 
NKRUMAH UNIVERSITY OF SCIENCE AND TECHNOLOGY, GHANA 
 
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by: Professor Richard W. Vachet 
 
We have developed a straight forward method that uses monolayer protected 
clusters (MPCs) and mixed monolayer protected clusters (MMPCs) as selective 
extraction and concentration probes for peptides. After extraction with these 
nanoparticles (NPs), the peptides are analyzed by MALDI-TOF-MS to obtain their 
mass fingerprints. Application of the method to a test library of 146 tryptic peptides 
showed that cationic MPCs/MMPCs target negatively charged peptides while the 
anionic MPCs/MMPCs target positively charged peptides. The extraction with these 
NPs is also accompanied by high concentration factors such they can be used to extract 
and concentrate microcystin-LR at levels below the WHO guideline of 1µg/L.  
vii 
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                                              CHAPTER 1 
INTRODUCTION 
Recent advancements in mass spectrometric instrumentation allow the masses 
and sequences of peptides to be sensitively determined, and this enables protein 
identification. Typically, proteins from cell lysates are separated with two-dimensional 
gel electrophoresis (2DE) and stained spots on the gel are excised and digested to 
produce peptides of different lengths and sequences. The resulting peptides are then 
separated by on-line HPLC, and the eluting peptides are ionized by ESI and are further 
fragmented to obtain sequence information. Spectra from selected peptides are 
compared with computer generated mass spectra from a sequence database to identify 
the protein.1 However, the complexity and the wide dynamic range of the biological 
matrices from which these biomolecules are derived can limit our ability to detect them 
efficiently. To take full advantage of powerful mass spectrometric instrumentation so 
that peptides can be adequately analyzed requires the use of highly efficient and 
selective extraction and concentration methods.  
A number of extraction and concentration techniques have been developed and 
applied to peptides prior to their analysis, with the two most successful ones being 
solid-phase extraction (SPE)2,3 and bioaffinity retention (BA) systems.4 In SPE, the 
sample to be extracted is passed through a cartridge, which retains them by adsorption. 
The adsorbed samples can then be eluted from the cartridge using the appropriate 
solvent (e.g. polar organic solvents such as methanol), 5 and the analytes of interest can 
be effectively concentrated by elution with a smaller volume than the initial loading 
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volume. Alternatively, the extracts can be reduced in volume by evaporation, resulting 
in increased sample concentration. Even though SPE is suitable for many applications, 
it has limited extraction capacity because of relatively low analyte specificity and 
relatively low surface areas. Sol gels have been investigated as materials for SPE 
because they offer good control over surface recognition sites and provide moderately 
high surface areas.6 These materials, however, tend to have recognition sites with a 
range of specificity and analyte access, and the very high surface area materials (i.e. 
aerogels) are very fragile. 
BA systems, on the other hand, use the natural affinity of the analyte of interest 
for its natural biological complement (e.g. a ligand immobilized on the surface of the 
stationary phase).7 BA systems rely on the reversible formation of complexes, and have 
been used as a part of the traditional 2DE-MS workflow for protein identification, often 
to deplete biological matrices of high abundance proteins so that proteins present at low 
concentrations can be detected. An example is the use of an affinity system fabricated 
by conjugating β-casein and bovine immunoglobulin G (IgG)-specific IgG with 
sepharose to remove major proteins including β-casein and IgG from bovine milk, 
which makes identification of low-abundance milk proteins possible.8 In general, BA 
systems use ligands that have long-term storage problems and limited utility under 
harsh conditions. In addition, BA systems use micron-sized support materials with 
relatively low surface-area-to-volume ratios, which may limit their extraction capacities 
due to limited recognition site loading.  
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Very recently, several researchers have demonstrated the extraction capabilities 
of nanometer-sized particles.9-18 As extraction agents, nanoparticles (NPs) have 
significant advantages over micron-sized materials, which are the standard support 
materials used in SPE and BA extraction systems. Most notable is a higher surface area-
to-volume ratio. As particle radius decreases from 1 µm to 10 nm, for example, the 
surface area-to-volume ratio increases 100-fold. This increase translates into much 
greater extraction capacity, and NPs have great potential in this regard. Indeed, several 
researchers have recently used the inherent extraction efficiency of NPs in conjunction 
with MALDI-MS analysis. Chen and co-workers have demonstrated that gold NPs 
coordinated with citrate and chloride ions (i.e. negatively-charged surfaces) can trap 
and concentrate positively-charged peptides from 100 nM solutions,9 while TiO2-coated 
Fe3O4 NPs can be used to selectively concentrate phosphopeptides at 500 pM 
concentrations.10 Gold NPs dissolved in toluene have also been used as part of a liquid-
liquid microextraction system to concentrate negatively-charged peptides present at µM 
concentrations in urine samples.11 Other NP materials such as silica,12,13 diamond 14, 
and zeolites 15 have also been used to concentrate peptides from very dilute solutions. 
Hsiao and co-workers have also employed C18 functionalized magnetic nanoparticles 
to enrich and identify phosphopeptides from phosphorylated myelin basic protein.16 
Chen et al. demonstrated that nanocomposites of ion oxide magnetic nanoparticles 
coated with sol-gel alumina can be used to selectively enrich phosphoproteins and 
phosphopeptides from tryptic digest products of proteins.17 Yang et al. have also 
derivatized calcium carbonate nanopaticels with poly(methyl methacrylate) and applied 
them to enrich peptides mixtures from very dilute solutions.18 
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In addition to high surface area-to-volume ratios, some NPs offer the ability to 
build materials with “bottom-up” design control. This feature enables the creation of 
particles with surface functionality that can selectively recognize a particular class of 
compound.19-29 In particular, monolayer-protected gold clusters (MPCs), which are 
core/shell NPs, provide many desirable attributes for the creation of selective extraction 
agents. MPCs can be formed via a one-pot synthesis.28 Their core size can be varied 
from < 1 nm to ~ 8 nm by controlling the thiol (shell)-gold (core) stoichiometry. The 
functionality at the surface and interior of the monolayer can be controllably varied 
through the thiol(s) used for capping. Furthermore, the functional diversity of MPCs 
can be easily extended by forming mixed monolayer protected clusters (MMPCs), 
which can be formed directly using mixed thiols during NP formation or by a place 
displacement reaction.29 Taken together, these features make MPCs and MMPCs 
attractive systems for developing specifically tailored NP extraction materials. 
The goal of this work is to use MPCs and MMPCs in a general methodology 
that will allow direct, efficient, and selective extraction and concentration of peptides 
from very dilute solution mixtures. These materials will be used in conjunction with 
MALDI-MS for efficient detection of these peptides. MALDI-TOF-MS will be used to 
detect the extracted/concentrated analytes because of its capability in the high-mass 
range and its sensitivity in the femtomole to picomole range. MALDI-TOF MS also has 
high sample transmission efficiency, which minimizes sample loss, rapid analysis times 
and relatively high tolerance for sample contamination. 
Microcystins, a family of hepato-toxic cyclic peptides will be another target for 
our NPs. This family of cyanotoxins is produced in lakes and other fresh water bodies 
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by bloom-forming cyanobacteria genera that include Microcystis, Anabaena, 
Planktothrix and Nostoc.30-32 To date, there are over 60 variants of microcystins that 
have been characterized and that differ in their toxicities, 33 with microcystin-LR being 
the most common in cyanobacteria; however, it is common to find more than one 
microcystin in a particular strain of cyanobacterium. Microcystins are potent hepato-
toxins (LD50 40–800 mg/kg (mice, intraperitoneal injection)), 34-37 and an inhibitory 
dosage (ID50) of 1-10 mg (per person) by an unspecified route of exposure has also been 
estimated.38The toxins have been implicated in the deaths of livestock and wildlife,39-42 
however, the most serious incident of human intoxication occurred in 1996, when the 
deaths of about 60 patients at a hemodialysis clinic in Brazil were attributed to 
microcystins, which were later identified in the clinic’s water supply.43-45 The toxins 
have also been suggested as potential biological warfare agents.38  
In structure, microcystins are made of five invariant amino acids namely, D-
alanine (position 1), D-methylaspartic acid (position 3), 3-amino-9-methoxy-2, 6, 8-
trimethyl-10-phenyl-4, 6-dienoic acid (Adda) (position 5), D-glutamic acid (position 6) 
and N-methyldehydroalanine (position 7) as well as two variant amino acids at positions 
2 and 4, which are normally L-amino acids (fig. 1.1).  
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Figure 1.1: General structure of microcystins (MCs), where R1 and R2 are variable L-
amino acids. 
 
 
The Adda moiety is a unique β-amino acid and is one of the invariant amino 
acids.46,47 The toxins are named according to the two variable L-amino acids at 
positions 2 and 4 (fig. 1.1). For example, microcystin-LR (MC-LR) contains the amino 
acids leucine (L) and arginine (R) at these positions.  At the molecular level, they are 
known to bind irreversibly to several serine/threonine protein phosphatases including 
protein phosphatase 1 (PP1) and protein phophatase 2A (PP2A) and thus inhibit these 
enzymes’ functions.48, 49  
The extent of human fatalities caused by microcystin toxicity has necessitated 
the development of fast, sensitive methods to detect these toxins. These methods should 
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be able to detect the toxin at concentrations below the WHO guideline of 1 µg/L.50 
These concentrations are, however, difficult to analyze and thus very efficient 
concentration and clean-up methods are needed prior to analysis. We anticipate that the 
high surface-area-to-volume of MPCs/MMPCs will afford the required extraction 
capacity to detect the toxins at levels below the WHO provisional guideline.  
The body of this thesis is divided into four chapters. Chapter 2 focuses on 
developing and testing a general protocol for selective extraction and concentration of 
peptides with MMPCs. Chapter 3 describes the evaluation of several different NPs, in 
order to understand the extraction selectively of these NPs for the target peptides. The 
use of different NPs enabled us to further understand the characteristic features of the 
NPs that allow them to function as highly efficient and selective extraction agents for 
peptides. In chapter 4, we describe the use MMPCs to extract and concentrate 
microcystin-LR from very dilute solutions, and finally, chapter 5 outlines the future 
direction of this work.   
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                                               CHAPTER 2 
GENERAL METHOD DEVELOPMENT 
In this chapter, we describe, the use of mixed monolayer protected clusters 
(MMPCs) to develop a method to selectively extract and concentrate peptides with 
specified physical characteristics from very dilute solutions. Two types of MMPCs 
were used, one is positively-charged (TmaNP (I)) and the other is negatively-charged 
(CxyNP). It is held that these nanoparticles interact with their targets mainly by means 
of complementary electrostatic interactions.51 In our experiments, we mixed the NPs 
with peptides  in a specified mole amount, and once extracted, the peptide-bound NP 
are directly analyzed by MALDI-TOF-MS in a manner that reduces sample handling 
and thus minimizes any associated sample losses. 
 
2.1 EXPERIMENTAL 
2.1.1 Materials and Reagents  
Human glucagon (19-29), T7-peptide, human ACTH (1-13) and kinetensin were 
obtained from Global Peptides Inc. Angiotensin I, bradykinin, α-cyano-4-
hydroxycinnamic acid (α-CHCA) and all chemicals for the NP fabrication were 
obtained from Aldrich. Tris-(hydroxymethyl) aminomethane (Tris) and tris-
(hydroxymethyl) aminomethane hydrochloride (Tris-HCl) were purchased from EM 
science. The water used in all the experiments was obtained from a Milli-Q water 
purification system (Millipore, Bedford, MA, USA). The Centricon filters and 
centrifuge tubes were purchased from Millipore Corporation.  
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2.1.2 Preparation of NP Systems 
Fabrication and characterization of the gold NP systems were accomplished via 
previously reported procedures. 52, 53 For the cationic NPs (TmaNP (I)), the octanethiol-
functionalized precursor was place exchanged with 11-trimethylammonium-
undecanethiol moieties 54 and for the anionic NPs (CxyNP), the octanethiol precursor 
was place exchanged with ω-thiol carboxylic acid units. 55 NMR analysis of the end 
groups of the TmaNP indicated that the trimethylammonium side chain functionality 
was 71% of the thiol monolayer. A 1:1 ratio of ω-thiol carboxylic acid to octanethiol 
was obtained for the CxyNP.     
 
 
  
Figure 2.1: Schematic of the extraction process for MALDI-MS analysis with nanoparticle 
systems. 
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2.1.3 Sample Extraction with NP’s 
Stock solutions of all the peptides except for glucagon were prepared in 
deionized water. Glucagon was prepared in a 70:30 ACN:H2O (v/v) because of its 
limited solubility in water. The peptide stock solutions were then diluted to working 
concentrations in a 25 mM Tris/Tris-HCl buffer at the desired pH. To extract the 
peptides from solution, a 50 - 250 µL solution of NP’s (2.5 – 50 µM) was added to an 
equal volume of a peptide solution in a 10000 MW Centricon cut-off filter. The mixture 
was vortexed for 8 – 10 minutes. The peptide-bound NPs were aggregated and 
separated from the reaction supernatant by centrifugation in an Allegra™ X-22R 
centrifuge (Beckman CoulterTM). The residue (peptide-bound NPs) and supernatant 
were then analyzed separately by MALDI time-of-flight (TOF) MS (fig. 2.1). For the 
pH-dependent experiments, 50 µL of a 5 µM NP solution was used to extract a 1 µM 
solution (50 µL) of angiotensin I. To test the selectivity of the NP systems for peptides 
with different pI values, 50 µL of a 5 µM NP solution was used to extract an equal 
volume of a 5 µM solution of each peptide except glucagon and the T7-peptide. These 
latter peptides were studied at concentrations of 100 µM for glucagon and 60 µM for 
the T7-peptide. These higher concentrations were used because these two peptides are 
inefficiently ionized by MALDI. 
 
2.1.4 MALDI TOF-MS  
All mass spectra were acquired in positive ion mode using an Omniflex® 
Reflectron TOF mass spectrometer (Bruker). Each mass spectrum was acquired by 
accumulation of 100 laser shots at 30% laser power. The matrix solution consisted of α-
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CHCA saturated in 70%ACN:30%H2O, 0.1% TFA (v/v). The dried-droplet method was 
used for all the samples. Typically, 1 µl of the residue or supernatant was mixed with 5 
µl of the matrix solution and an aliquot (0.5 - 1 µl) of this mixture was applied to the 
stainless steel probe and allowed to air dry before the MALDI-TOF MS measurements. 
 
2.2 RESULTS AND DISCUSSION 
2.2.1 Peptide-NP Mole Ratio 
We have used both positively-charged (TmaNP (I)) and negatively-charged 
(CxyNP) NPs to extract and concentrate several different peptides from solution. To 
study the effect the peptide-NP mole ratio on the resulting MALDI ion signal, 
angiotensin I and TmaNP (I) were used. A 50 µL solution of 1 µM angiotensin was 
extracted with the same volume but varying concentrations (5 - 50 µM) of TmaNP (I). 
Figure 2.2 displays the plot of MALDI ion abundance versus peptide-NP mole ratio. 
The MALDI ion abundance increases to a maximum at an optimum peptide-NP ratio 
value of 1:10. Above this ratio, ion abundance drops and then levels off with increasing 
amount of the NPs. This optimum occurs because of two competing processes that are 
both dependent on the NP concentration – extraction capacity and MALDI signal 
suppression. As the NP concentration increases a greater percentage of the peptide is 
extracted, and thus the MALDI signal associated with the residue increases and the 
signal associated with the supernatant decreases. At high NP concentrations, though, 
NP-induced ion suppression is observed. The 1:10 mole ratio represents the optimum 
trade-off between these competing factors. To overcome the suppression caused by the 
presence of the NPs during the MALDI process, 5 µL of a 60 µM solution of sodium 
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cyanide was added to the peptide-NP conjugate after centrifugation to induce 
dissolution of the gold core of the NP before analysis. The MALDI ion signal is 
significantly improved (triangles in Fig. 2.2).It is important to note that recent work by 
Russell and co-workers demonstrated that gold NPs themselves could be used as a 
MALDI matrix when used at ratios of 1 x 107-109 analyte molecules to 1 NP.56 In our 
experiments, much higher ratios of NPs are necessary for effective extraction and 
concentration, and at the ratios studied (e.g. 1:10 peptide:NP) the NP’s did not act as 
effective matrices alone. 
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Figure 2.2: MALDI ion abundances of angiotensin I as a function of peptide:NP ratio after 
extraction with the TmaNP (I). The squares represent the MALDI signal associated with the 
peptide-NP residue, the circles represent the MALDI signal associated with the supernatant and 
the triangles represent the MALDI signal associated with residue after removal of the NPs with 
NaCN. The error bars associated with each measurement represent one standard deviation from 
the mean. 
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2.2.2 Extraction Efficiency as a Function of pH 
 
The NPs used in this study were designed to interact with the target peptides 
through complementary electrostatic interactions. To confirm that the NPs function in 
this fashion, the MALDI ion abundance of angiotensin was studied as a function of 
extraction solution pH. Figure 2.3 shows that the residue (peptide-NP conjugate) ion 
signal increases with increasing pH, whereas the supernatant signal decreases. Because 
the ionization state of the trimethylammonium functional groups is independent of pH, 
the solution charging of angiotensin is what gives rise to this pH-dependent behavior. 
Angiotensin has an isoelectric point (pI) of 7.7, so at pH values below 7.7 the peptide 
has a net positive charge and is not extracted very efficiently with the positively-
charged NPs.  
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Figure 2.3: MALDI ion abundances of angiotensin I after extraction with TmaNP (I) at 
different pH values. The squares represent the MALDI signal associated with the peptide-NP 
residue, and the triangles represent the MALDI signal associated with the supernatant. The error 
bars associated with each measurement represent one standard deviation from the mean. 
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At pH values above 7.7, though, angiotensin has a net negative charge and is extracted 
more efficiently. These observations suggest that complementary electrostatic binding 
is the main factor controlling extraction of the peptide by TmaNP (I). Even so, 
angiotensin can still be extracted, albeit inefficiently, at low pH values, which can be 
attributed to capture of the peptide via hydrophobic interactions between the peptide 
and the C8 chains that account for about 30% of the NP surface. An interesting, yet not 
fully understood observation is the relatively low residue and supernatant signals 
measured when the peptide is extracted at pH values near its pI. If extraction efficiency 
is poor at pH values around 7.7 as indicated by the low residue signal, then one would 
expect relatively high MALDI signals for the supernatant, but this is not observed. A 
temptation is to ascribe this poor supernatant signal to low peptide solubility around its 
pI, but the low concentrations used in this experiment (i.e. 1 µM) lessen the likelihood 
of this explanation. This phenomenon, which is observed for several peptides that are 
extracted near their pIs, needs to be further investigated.  
Table 1.1: Peptides used in the nanoparticle extraction experiments. 
 
Peptide Sequence pIa
ACTH (1-13) SYSMEHFRWGKPV 9.3 
T-7 peptide MASMTGGQQMG 6.1 
Kinetensin IARRHPYFL 11.2 
Glucagon (19-29) AQDFVQWLMNT 3.8 
Bradykinin RPPGFSPFR 12.5 
Angiotensin I DRVYIHPFHL 7.7 
 
a Theoretical values of the peptide pI’s were obtained using a software tool located at 
http://www.bioweb.pasteur.fr/seqanal/tmp/pepstats/ 
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2.2.3 Extraction Capacity as a Function of Peptide pI 
Given the observation that electrostatic interactions dominate the extraction 
efficiency, we tested the selectivity of the NPs for peptides of varying pI values (Table 
2.1). Figure 2.4 summarizes the resulting data by plotting extraction capacities as a 
function of peptide pI. Extraction capacity is defined as the ratio of the MALDI ion 
abundance of each protonated peptide (M+H)+ in the residue (Ir) to the ion abundance in 
the reaction supernatant (Is) (K=Ir/Is).  The peptide extraction capacity correlates with 
peptide pI, and as might be expected, the two NP systems (TmaNP (I) and CxyNP) 
exhibit opposite selectivity for the peptides. The cationic NPs more efficiently extract 
peptides with low isoelectric points because these peptides are negatively charged under 
the solution conditions that were used (i.e. pH 7.4). For example, glucagon, which has a 
pI of 3.7, is extracted fairly efficiently by TmaNP (I), whereas, bradykinin with a pI of 
12.5 is poorly extracted by these positively-charged NPs. In contrast, the anionic NPs 
more efficiently extract peptides with high pIs because these peptides are positively 
charged under the solution conditions that were used (i.e. pH 8.6). As an example of 
this trend, bradykinin is very efficiently extracted, but glucagon is not. The TmaNP (I)’s 
increase in extraction capacity with decreasing peptide pI (Fig. 2.4a) is explained by the 
increase in the effective negative charge of the peptides with low pI’s, while the 
CxyNP’s increase in extraction capacity with increasing pI (Fig. 2.4b) is due to the 
increase in the effective positive charge of the peptides with high pI’s.  Just as was seen 
with angiotensin in Figure 2.3, both TmaNP (I) and CxyNP can still extract peptides of 
the same net charge, but they do so with lower efficiency. This result again indicates 
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that non-electrostatic interactions, possibly hydrophobic and/or hydrogen-bonding 
interactions, play a minor role in the extraction processes involving these NPs. 
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Figure 2.4: Extraction capacity of TmaNP(I) (A) and CxyNP (B) as a function of peptide 
isoelectric point. The pH of the solution used to extract peptides with the TmaNP(I) was 7.4, 
while the pH of the solution used to extract peptides with the CxyNP was 8.6. The peptides used 
in these experiments are shown in Table 1. The error bars associated with each measurement 
represent one standard deviation from the mean. 
 
 
2.2.4 Preconcentration 
Because the NPs used here can be easily concentrated in solution via 
centrifugation, their selectivity is accompanied by high concentration factors. Figure 2.5 
shows MALDI mass spectra of bradykinin before and after extraction with CxyNP. 
Virtually no identifiable ion signal is observed for bradykinin when a 1.25 nM solution 
of the peptide is analyzed directly (Fig. 2.5a). However, upon extraction and 
concentration of the same sample solution with CxyNP, the protonated species of 
bradykinin is easily observable in the mass spectrum (Fig. 2.5b). Figure 2.5c displays 
the results of bradykinin extraction and concentration at a concentration of 500 pM. As 
A
B
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might be expected, no identifiable protonated species is observed for bradykinin before 
extraction/concentration at 500 pM (data not shown). 
 
0 200 400 600 800 1000 1200 1400
0
2000
4000
6000
8000
10000
12000
14000
16000
18000
20000
22000
m/z
Io
n 
A
bu
nd
an
ce
1040 1050 1060 1070 1080
0
100
200
300
400
500
600
700
 
0 200 400 600 800 1000 1200 1400
0
2000
4000
6000
8000
10000
12000
14000
16000
18000
20000
22000 (M+H)
+
(M+H)+
Io
n 
A
bu
nd
an
ce
m/z
1040 1050 1060 1070 1080
0
100
200
300
400
500
600
700
 
0 200 400 600 800 1000 1200 1400
0
2000
4000
6000
8000
10000
12000
14000
16000
18000
20000
(M+H)+
(M+H)+
m/z
Io
n 
A
bu
nd
an
ce
1040 1050 1060 1070 1080
0
20
40
60
80
100
 
Figure 2.5: MALDI mass spectra of a 1.25 nM solution of bradykinin ([M+H]+ = m/z 1060.5) 
before (A) and after (B) extraction and concentration with CxyNP. (C) MALDI mass spectrum 
of a 500 pM solution of bradykinin after extraction and concentration with CxyNP. 
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2.3 CONCLUSION 
In summary, we have developed a straightforward method that employs 
functionalized NP systems as selective and efficient extraction agents for peptides from 
dilute solutions. By designing the NPs with cationic or anionic functional groups, we 
have demonstrated that these NPs can selectively extract negatively- or positively-
charged peptides, respectively, with efficiencies that are dependent upon peptide pI and 
solution pH. The extraction selectivity is coupled with a significant preconcentration 
effect such that 500 pM solutions of some peptides can be analyzed when treated with 
the appropriate NPs. The high extraction capacity is attributed to the very high surface 
area-to-volume ratios associated with the small size (~ 2 nm diameter) of the NP’s. The 
small dimensions of the NPs also allow them to be used directly in the MALDI analysis 
without substantial losses to sensitivity or mass spectral resolution as long as the 
appropriate NP concentration is chosen. Direct analysis of the NPs has practical 
advantages too as it minimizes sample manipulation and in doing so avoids sample 
losses and contamination while reducing analysis time. Given the positive attributes of 
these NPs and the ease with which they can be combined with MALDI-MS, the 
approach described here has several potential applications. For example, cationic NPs 
might be used to selectivity concentrate proteolytic peptides with low pIs, and the fact 
that the extracted peptides have low pI values could be used as a constraint during 
database searches for protein identification. Furthermore, because the MMPCs can be 
readily fabricated with a wide range of surface functionality, the selectivity of the NPs 
can be tuned for even more selective fractionation of complex mixtures. This feature 
could make these NPs suitable for targeted protein extraction from cell lysates. 
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                                                           CHAPTER 3 
FACTORS AFFECTING THE EXTRACTION SELECTIVITY OF THE 
NANOPARTICLES 
Biological matrices, for example, cell lysates are complex in composition and 
possess wide dynamic range. Highly selective and effective extraction agents are thus 
needed to successfully fractionate them. To obtain the most efficient extractions for 
selected targets, the factors that influence the selectivity of our NPs have to be well 
understood so that they can be correctly tuned for efficient fractionation.  
While our preliminary results [chapter 2] indicate that peptide charge appears to 
be the dominant factor controlling the extraction, it is clearly not the only factor. Other 
factors might control the extraction efficiency, and these factors are not adequately 
accounted for by this limited set of peptides. In this chapter therefore, we describe our 
studies of the factors that affect the extraction selectivity of the NPs for the peptides. 
Five different types of NPs were used to extract and concentrate several peptides from a 
test library. The test library was created from tryptic digests of several known proteins. 
The different NPs were separately used to extract and concentrate the peptides from 
dilute solutions of the different digest samples (at the same solution concentrations), 
and both the residue and the reaction supernatant were separately analyzed by MALDI-
TOF MS after removal of the NPs from the mixture for comparison. 
3.1 EXPERIMENTAL 
3.1.1 Materials and Reagents  
All proteins, α-cyano-4-hydroxycinnamic acid (α-CHCA), Tris (2-carboxyethyl) 
phosphine hydrochloride (TCEP) and all chemicals for the NP fabrication were 
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purchased from Aldrich. Tris-(hydroxymethyl) aminomethane (Tris) and tris-
(hydroxymethyl) aminomethane hydrochloride (Tris-HCl) were purchased from EM 
Science. Sequencing grade modified trypsin (Promega, Madison, WI) was used for all 
the digestions. The water used in all the experiments was obtained from a Milli-Q water 
purification system (Millipore, Bedford, MA, USA). The Centricon filters and 
centrifuge tubes were purchased from Millipore Corporation.  
 
3.1.2 Protein Digestion 
Tryptic digestions were carried out on myoglobin, cytochrome C, hemoglobin, 
bovine serum albumin (BSA), lysozyme and ovalbumin to produce peptides of different 
lengths and sequences for the extraction experiments. Each of the proteins was digested 
with trypsin at a concentration ratio of 50:1 (protein/trypsin). To facilitate the digestion, 
15 µL of acetonitrile was first added to a 50 µL solution of the protein (625 µM), and 
the mixture was heated at 60° C for 30 min before adding trypsin. After cooling the 
protein solution to room temperature, trypsin was added to the appropriate 
concentration ratio in a 50 mM Tris-Tris/HCl buffer at pH 7.6. The protein/enzyme 
mixture was then incubated at 37 ºC for 18 h. Each protein digest was analyzed 
separately by MALDI-TOF MS to confirm the proteins identity, and then it was 
extracted with the NPs. Proteins that contain disulfide bridges were reduced with TCEP 
before incubation with acetonitrile and subsequent digestion with trypsin. Six proteins 
were digested in all, and the experiments resulted in a data set of 145 peptides. 
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3.1.3 Preparation of NP systems 
 Fabrication and characterization of the gold NP systems (see Table 3.1) were 
accomplished via previously reported procedures (see chapter 2). For the positively 
charged NPs, TmaNP (I) is capped with 30% free alkanethiol and 70% 
trimethylammonium groups, and TmaNP (II) is capped with 100% trimethylammonium 
groups.  
 
Table 3.1: Functionalized nanoparticles used for the extraction experiments. 
 
 
 
  
 
 
 
The trimethylammonium ions in both types of NPs are counter-balanced in solution by 
bromide ions. LysNP is functionalized with 100% alkanethiols terminated with lysine 
groups. For the negatively charged NPs, CxyNP is functionalized with both free 
alkanethiols and carboxylate-capped alkanethiol groups, which are counter-balanced in 
solution by sodium ions. SoaNP is functionalized with 100% alkanethiols that are 
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capped with sulfonate groups via tetraethyleneglycol (TEG) linkers. The sulfonate ions 
are counter-balanced in solution by sodium ions.  
 
3.1.4 Sample Extraction with NP’s 
Stock solutions of all the digests were prepared in deionized water. The digest 
stock solutions were diluted to working concentrations (2 µM) in a 25 mM Tris/Tris-
HCl buffer at the desired pH. To extract the peptides from the digest solutions, a 150 µL 
solution of NP’s (20 µM) was added to an equal volume of a peptide (2 µM) solution in 
a 10000 MW Centricon cut-off filter, and the mixture was vortexed for 8 – 10 minutes. 
The peptide-bound NPs were aggregated and separated from the reaction supernatant by 
centrifugation in an Allegra™ X-22R centrifuge (Beckman CoulterTM). MALDI-TOF 
MS analysis is then performed on the residue and the supernatant after the gold NPs 
have been removed from the residue. A mixture of 5% trifluoroacetic acid (TFA), 
75%H2O, and 20% actonitrile (ACN) was used as the releasing agent for the extraction 
experiments involving TmaNP (II), SoaNP and CxyNP. Aqueous sodium cyanide 
(NaCN) was used as the releasing agent for the extractions involving TmaNP (I), while 
a mixture of 5%NH3/65%H2O/30%ACN was used for the LysNP experiments. 
3.1.5 MALDI TOF-MS  
 
All mass spectra were acquired in positive ion mode using an REFLEX III 
(Bruker Daltonics) in reflectron mode. The laser fluence was adjusted for optimum 
resolution and peak intensity in the 600 – 4000 m/z range. Each mass spectrum was 
acquired by accumulation of 60 laser shots. The matrix solution consisted of α-CHCA 
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saturated in 70%ACN:30%H2O with 0.1% TFA(v/v). The dried-droplet method was 
used for all the samples. Typically, 1 µl of the residue or supernatant was mixed with 5 
µl of the matrix solution and an aliquot (1 µl) of this mixture was applied to the 
stainless steel probe and allowed to air dry before the MALDI-TOF-MS measurements. 
 
3.2 RESULTS AND DISCUSSION 
Figure 3.1 displays plots of extraction capacity (K) vs. peptide isoelectric point 
(pI) for extractions with the five different NPs. K is a measure of how well the NPs 
extracted the peptides and is expressed as a ratio of the MALDI ion abundance of each 
protonated peptide in the residue to the MALDI ion abundance of the same protonated 
peptide in the reaction supernatant (see chapter 1). The peptide pI values were 
computed using the PEPSTATS software.57 In all, five different types of NPs, namely 
TmaNP (I), CxyNP, TmaNP (II), LysNP and SoaNP (table 3.1), were screened against a 
test library of 146 peptides (table 3.2) to learn about the factors that affect their 
extraction selectivity.  
For the extraction experiments involving LysNP, SoaNP and the two 
trimethylammonium functionalized NPs (i.e. TmaNP (I) and TmaNP (II)); the pH of the 
extraction mixture was fixed at 7.4 using a Tris/Tris-HCl buffer. At this solution pH, 82 
of the 146 peptides are negatively-charged (i.e. have pI values below the solution pH), 
61 are positively-charged (i.e. have pI values above the solution pH), and the remaining 
3 peptides are neutral (i.e have pI values equal to the solution pH). CxyNP aggregates at 
acidic and even neutral pH, and for this reason, the extractions involving this NP were 
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Figure 3.1: Extraction capacity of TmaNP (I), LysNP, SoaNP, CxyNP and TmaNP (II) as a 
function of peptide isoelectric point.  
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Table 3.2 a: Tryptic peptides used in the extraction experiments (cationic NPs).  
 
TmaNP (I) TmaNP (II) LysNP
m/z Sequence # Amino acid sequence pI Hb KD K Sd (±) K Sd (±) K Sd (±)
604.00 56-60 GITWK (5) 9.7 15.88 -1.40 0.90 0.20 1.00 0.10 2.40 0.20
634.00 9-13 IFVQK (5) 9.7 14.61 4.10 1.30 0.30 0.90 0.20 1.80 0.00
678.00 74-79 YIPGTK (6) 9.3 10.36 -3.39 0.30 0.10 4.30 0.80 1.30 0.30
779.34 80-86 MIFAGIK (7) 9.69 27.42 11.20 1.30 0.10 0.50 0.10 2.90 0.70
861.00 1-8 GDVEKGKK (8) 9.4 4.53 -15.30 0.70 0.30 0.80 0.10 1.50 0.40
907.00 80-87 MIFAGIKK (8) 10.1 26.89 7.29 1.40 0.80 0.60 0.10 1.20 0.20
964.00 92-99 EDLIAYLK (8) 4.2 27.29 1.69 24.40 6.00 59.10 16.60 36.10 2.40
1169.00 28-38 TGPNLHGLFGR (11) 10.6 25.01 -4.30 1.30 0.10 1.50 0.20 1.50 0.20
1350.00 89-99 TEREDLIAYLK (11) 4.4 26.99 -6.99 9.70 2.40 1.60 0.20 1.90 0.40
1470.00 40-53 TGQAPGFTYTDANK (14) 6.2 18.89 -13.80 12.00 3.30 0.70 0.10 3.80 2.20
1479.19 89-100 TEREDLIAYLKK (12) 6.6 25.42 -10.89 1.30 0.20 2.00 0.10 3.10 0.40
1495.00 61-72 EETLMEYLENPK (12) 3.8 32.15 -19.40 53.70 4.10 13.20 1.50 74.20 9.80
1508.95 92-104 EDLIAYLKKATNE (13) 4.43 30.3 0.30 1.20 0.10 1.20 0.30 4.10 0.60
1598.00 39-53 KTGQAPGFTYTDANK (15) 9.3 17.4 -17.70 1.30 0.30 1.70 0.40 2.50 0.90
1607.00 87-99 KKTEREDLIAYLK (13) 9.2 25.75 -14.79 3.40 1.00 1.00 0.10 1.40 0.20
1623.00 61-73 EETLMEYLENPKK (13) 4.2 31.06 -15.50 20.10 3.70 2.80 0.80 2.20 0.40
1634.85 9-22 IFVQKCAQCHTVEK (14) 8.24 20.23 -8.10 1.10 0.10 1.80 0.30 3.90 0.70
748.00 133-138 ALELFR (6) 6 26.75 4.19 2.20 0.10 4.00 0.50 9.50 1.10
941.00 145-153 YKELGFQG (8) 6 20.86 -6.40 0.90 0.30 2.90 0.30 3.00 0.60
1062.00 43-50 FDKFKHLK (8) 9.7 23.65 -8.99 0.80 0.10 1.90 0.40 1.60 0.20
1272.00 32-42 LFTGHPETLEK (11) 5.4 23.1 -7.10 1.00 0.20 1.20 0.50 11.90 1.10
1361.00 46-56 FKHLKTEAEMK (11) 8.5 19.05 -12.30 2.40 0.70 3.80 1.30 1.70 0.10
1378.80 64-77 HGTVVLTALGGILK (14) 8.76 40.29 16.40 2.00 0.20 4.60 1.70 2.70 0.60
1502.00 118-132 HPGDFGADAQGAMTK (15) 5.2 20.18 -11.00 2.00 0.50 3.70 1.30 10.90 2.50
1507.00 63-77 KHGTVVLTALGGILK (15) 10.8 38.79 12.49 1.30 0.30 1.60 0.20 1.40 0.30
1554.00 140-153 NDIAAKYKELGFQG (14) 7 27.43 -9.20 1.50 0.10 1.50 0.20 2.10 0.30
1607.00 17-31 VEADIAGHGQEVLIR (15) 4.6 27.29 2.29 92.40 17.30 190.40 12.10 54.40 8.20
1816.00 1-16 GLSDGEWQQVLNVWGK (16) 5.2 41.59 -9.20 40.10 1.40 41.40 6.30 1.50 0.10
1853.00 79-95 GHHEAELKPLAQSHATK (17) 7 18.04 -18.39 1.70 0.30 1.10 0.30 5.10 0.40
1885.02 103-118 YLEFISDAIIHVLHSK (16) 6.5 45.92 9.70 60.20 3.60 32.40 6.30 1.30 0.10
1982.00 78-95 KGHHEAELKPLAQSHATK (18) 8.5 16.14 -22.29 0.60 0.10 0.90 0.20 4.20 0.40
2861.36 17-42 VEADIAGHGQEVLIRLFTGHPETLEK (26) 4.7 37.29 -4.80 1.20 0.20 1.40 0.20 1.00 0.30
3405.33 1-31 GLSDGEWQQVLNVWGKVEADIAGHGQEVLIR (31) 4.2 48.53 -6.89 67.70 17.50 74.00 2.20 1.50 0.20
648.09 280-284 VYLPR (5) 9.3 15.64 0.60 4.16 0.84 0.67 0.09 2.60 0.60
780.16 105-110 LYAEER (6) 4.3 8.41 -7.20 1.68 0.35 2.77 1.21 5.20 0.30
823.14 219-226 VASMASEK (8) 6 6.87 0.70 0.14 0.03 0.71 0.15 4.40 1.00
887.21 278-284 IKVYLPR (7) 10 22.45 1.20 1.47 0.20 2.44 0.20 3.60 0.30
906.09  181-187 VYLPRMK (7) 10.5 21.4 -1.40 0.90 0.10 1.28 0.46 1.80 0.50
976.16 182-189 GLWEKAFK (8) 9.5 26.9 -4.20 1.80 0.37 1.66 1.24 1.70 0.10
1015.37 277-284 KIKVYLPR (8) 10.9 24.01 -2.70 3.85 0.39 1.26 0.16 4.50 0.80
1062.58  47-55 DSTRTQINK (9) 9.7 6.45 -16.60 2.64 0.28 0.31 0.20 2.60 0.80
1080.99  219-228 VASMASEKMK (10) 9.5 13.8 -1.30 2.58 0.39 0.75 0.15 2.00 0.10
1190.23  360-369 ADHPFLFCIK (10) 7.4 33.56 6.00 0.90 0.00 0.64 0.29 2.00 0.20
1209.39 190-199 DEDTQAMPFR (10) 3.9 19.14 -14.30 1.19 0.33 0.55 0.06 7.90 1.70
1345.57 370-381 HIATNAVLFFGR (12) 10.6 36.49 9.40 7.43 1.01 17.36 5.26 2.10 0.20
1467.19 111-122 YPILPEYLQCVK (12) 6.2 34.8 2.10 2.57 0.49 1.29 0.64 7.60 0.80
1555.53 187-199 AFKDEDTQAMPFR (13) 4.4 25.23 -13.60 28.08 2.16 112.51 7.95 16.10 2.00
1581.52 264-276 LTEWTSSNVMEER (13) 4 26.63 -12.50 39.56 3.35 32.22 4.05 74.40 9.50
1687.71 127-142 GGLEPINFQTAADQAR (16) 4.2 29.68 -8.60 19.30 2.35 349.29 122.14 12.50 3.10
1709.85 264-277 LTEWTSSNVMEERK (14) 4.5 26.04 -16.40 13.20 1.65 9.92 2.13 5.90 2.00
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Table 3.2 a (continued) 
TmaNP (I) TmaNP (II) LysNP
m/z Sequence # Amino acid sequence pI Hb KD K Sd (±) K Sd (±) K Sd (±)
1774.80 323-339 ISQAVHAAHAEINEAGR (17) 6.5 20.99 -3.90 26.85 2.61 156.42 30.50 30.00 6.00
1859.91 143-158 ELINSWVESQTNGIIR (16) 4.3 37.43 -4.10 202.94 23.33 246.30 73.85 115.70 14.50
2250.14 123-142 ELYRGGLEPINFQTAADQAR (20) 4.4 35.58 -14.10 15.39 2.13 3.81 3.31 6.50 2.60
2281.23 85-104 DILNQITKPNDVYSFSLASR (20) 6.4 39.65 -6.50 10.12 2.03 2.53 1.04 8.90 4.30
2461.24 159-181 NVLQPSSVDSQTAMVLVNAIVFK (23) 6.3 46.23 15.30 6.42 0.84 1.00 0.00 1.70 0.40
729.59 1-7 VLSPADK (7) 6.3 10.1 0.00 0.22 0.03 1.58 0.09 3.00 1.00
766.93 201-207 VKAHGKK (7) 11.1 2.1 -9.30 0.43 0.08 2.67 0.17 3.40 1.00
819.03 93-99 VDPVNFK (7) 6.3 17.65 -1.30 0.08 0.01 2.22 0.32 2.90 1.80
931.89 150-158 SAVTALWGK (9) 9.7 23.96 4.90 1.16 0.12 1.05 0.14 3.80 1.80
951.99 142-149 VHLTPEEK (8) 5.4 13.28 -8.40 1.39 0.40 2.07 0.36 5.10 0.30
973.93 8-16 TNVKAAWGK (9) 10.8 16.62 -5.50 2.80 0.49 1.66 0.40 3.50 1.30
1071.03 32-40 MFLSFPTTK (9) 9.7 32.47 3.60 1.33 0.21 3.07 0.71 5.50 0.70
1087.13 91-99 LRVDPVNFK (9) 9.7 23.68 -2.00 1.10 0.26 1.36 0.04 3.50 0.20
1126.01 237-245 LHVDPENFR (9) 5.4 21.86 -9.00 28.41 1.73 26.73 6.04 37.50 4.60
1150.02 274-285 VVAGVANALAHK (12) 9.7 22.62 12.60 4.59 0.57 1.02 0.23 4.20 2.80
1170.99 1-11 VLSPADKTNVK (11) 9.5 13.39 -3.90 1.70 0.31 1.60 0.12 7.10 4.60
1252.13 128-139 FLASVSTVLTSK (12) 9.7 29.07 12.90 1.25 0.37 6.47 2.84 2.30 0.90
1269.04 140-149 YRVHLTPEEK (10) 7.5 17.65 -14.20 0.65 0.31 1.90 0.36 1.60 0.10
1274.12 172-181 LLVVYPWTQR (10) 9.3 33.32 3.50 3.64 0.94 54.81 6.74 7.50 0.40
1314.10 159-171 VNVDEVGGEALGR (13) 3.9 21.19 -1.50 34.62 3.52 51.05 14.14 82.20 7.30
1378.12 262-273 EFTPPVQAAYQK (12) 6.4 21.68 -9.00 3.68 1.35 2.95 0.70 7.20 4.00
1422.00 224-236 GTFATLSELHCDK (13) 5.4 28.82 -2.00 1.50 0.50 2.07 0.60 4.90 1.90
1449.15 274-287 VVAGVANALAHKYH (14) 9.3 24.67 8.10 1.46 0.34 1.46 0.24 2.00 0.20
1529.17 17-31 VGAHAGEYGAEALER (15) 4.5 20.9 -5.50 63.02 5.51 106.27 9.65 131.90 14.00
1669.37 208-223 VLGAFSDGLAHLDNLK (16) 5.4 36.74 6.60 10.14 2.28 14.37 3.08 3.80 0.70
1719.77 246-261 LLGNVLVCVLAHHFGK (16) 8.6 39.24 20.30 1.33 0.09 1.52 0.04 2.70 1.00
1798.36 207-223 KVLGAFSDGLAHLDNLK (17) 7.5 38.19 2.70 2.13 0.87 1.65 0.24 2.40 0.10
1834.44 41-56 TYFPHFDLSHGSAQVK (16) 7.7 31.7 -7.50 17.37 2.54 18.37 1.74 13.60 2.90
2060.05  182-200 FFESFGDLSTPDAVMGNPK (19) 3.9 38.05 -4.10 1.40 0.40 6.72 1.95 4.50 0.50
606.08 1-5 KVFGR (5) 11.7 9.6 -1.80 1.17 0.39 0.12 0.02 4.00 1.00
874.26 15-21 HGLDNYR (7) 7.5 11.54 -12.60 1.15 0.27 0.73 0.08 22.70 5.00
936.17 62-68 WWCNDGR (7) 6.2 19.77 -11.20 1.43 0.32 4.55 1.88 6.80 1.50
1030.53 14-21 RHGLDNYR (8) 9.3 12.35 -17.10 1.25 0.09 1.01 0.17 6.00 2.90
1045.44 117-125 GTDVQAWIR (9) 6.3 22.94 -2.99 10.42 4.89 20.41 0.21 56.20 4.80
1268.47 22-33 GYSLGNWVCAAK (12) 8.5 29.56 2.90 0.33 0.21 0.19 0.01 5.70 1.30
1428.56 34-45 FESNFNTQATNR (12) 6.4 16.15 -16.80 2.50 2.01 10.26 2.06 20.50 1.80
1450.48 2-14 VFGRCELAAAMKR (13) 9.8 25.08 3.80 1.64 0.33 1.26 0.36 7.60 2.20
1675.90 98-112 IVSDGNGMNAWVAWR (15) 6.3 32.93 0.00 5.42 2.35 29.54 3.84 15.60 3.30
1753.95 46-61 NTDGSTDYGILQINSR (16) 4.1 26.96 -14.30 29.30 4.06 49.13 7.02 143.80 11.30
609.73 500-504 AFDEK (5) 4.2 4.92 -6.30 4.60 0.40 5.15 1.18 1.30 0.20
649.09 199-204 CASIQK (6) 8.5 4.44 0.60 1.20 0.20 0.84 0.10 4.10 4.50
658.03 94-98 QEPER (5) 4.3 1.65 -16.60 5.90 1.60 4.58 1.28 1.60 0.10
688.29 212-217 AWSVAR (6) 10.5 13.09 1.60 0.80 0.10 5.03 0.46 1.20 0.10
701.08 174-180 GACLLPK (7) 8.5 17.65 6.00 2.50 0.50 1.38 0.50 1.60 0.40
712.15 5-10 SEIAHR (6) 7.6 4.99 -5.70 1.10 0.30 1.25 0.24 1.40 0.10
733.06 188-194 VLTSSAR (7) 10.5 7.88 3.00 1.10 0.20 1.11 0.23 1.20 0.10
752.19 317-322 NYQEAK (6) 6.4 3.1 -13.90 2.70 0.80 1.65 0.11 1.80 0.40
787.91 233-239 LVTDLTK (7) 6.3 17.02 2.99 3.30 0.20 3.31 0.56 0.50 0.10
818.03 538-544 ATEEQLK (7) 4.3 6.4 -9.50 1.10 0.30 1.18 0.29 1.90 0.20
840.89 459-465 LCVLHEK (7) 7.4 15.76 3.70 0.30 0.10 0.32 0.10 0.90 0.20
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 Table 3.2 a (continued) 
TmaNP (I) TmaNP (II) LysNP
m/z Sequence # Amino acid sequence pI Hb KD K Sd (±) K Sd (±) K Sd (±)
846.90 218-224 LSQKFPK (7) 10.8 15.69 -7.10 4.70 0.30 3.27 0.24 1.10 0.20
886.30 107-114 DDSPDLPK (8) 3.8 12.43 -14.60 2.60 0.10 1.66 0.39 1.40 0.50
922.05 225-232 AEFVEVTK (8) 4.3 20.05 1.40 2.70 0.30 0.78 0.12 1.20 0.30
927.36 137-143 YLYEIAR (7) 6.5 24.44 -0.50 8.90 1.19 116.57 14.66 17.80 0.90
974.34 13-20 DLGEEHFK (8) 4.4 16.23 -11.40 22.80 2.80 11.20 3.03 7.20 2.10
977.36 99-106 NECFLSHK (8) 7.4 16.6 -5.80 5.10 1.00 3.61 0.22 2.10 0.10
1011.11 389-396 QNCDQFEK (8) 4.2 7.55 -16.09 4.20 0.30 2.76 0.35 3.30 0.30
1014.57 525-533 QTALVELLK (9) 6.3 32.23 5.80 4.00 1.20 2.43 1.10 2.10 0.10
1050.39 564-573 EACFAVEGPK (10) 4.4 19.69 0.20 6.10 2.00 6.54 2.46 1.80 0.30
1084.59 137-144 YLYEIARR (8) 9.2 24.29 -5.00 6.23 0.21 69.89 3.26 1.10 0.20
1144.68 212-221 AWSVARLSQK (10) 11.7 21.64 -2.80 5.00 1.00 8.70 0.88 0.80 0.30
1163.47 42-51 LVNELTEFAK (10) 4.3 28.48 1.30 26.20 0.40 10.72 5.33 9.00 1.10
1197.56 313-322 DVCKNYQEAK (10) 6.3 6.24 -14.60 6.90 0.40 47.16 13.36 1.10 0.10
1202.63 195-204 QRLRCASIQK (10) 11.5 11.9 -8.10 3.80 0.30 6.45 2.47 4.40 0.80
1249.39 11-20 FKDLGEEHFK (10) 5.5 22.54 -12.50 5.40 0.60 7.74 4.98 4.80 0.50
1283.67 337-347 HPEYAVSVLLR (11) 7.5 32.31 2.89 18.86 5.59 63.66 8.64 4.10 0.20
1293.68 222-232 FPKAEFVEVTK (11) 6.4 27.48 -1.30 30.70 5.60 117.64 12.30 1.70 0.30
1305.61 378-388 HLVDEPQNLIK (11) 5.5 25.69 -6.40 48.50 5.70 19.08 7.40 14.50 4.40
1345.51 174-185 GACLLPKIETMR (12) 6.2 28.89 3.70 6.90 0.20 5.37 2.62 9.20 1.60
1361.09 65-76 SLHTLFGDELCK (12) 5.5 30.18 0.70 7.50 0.20 4.88 4.44 1.40 0.20
1386.31 262-273 YICDNQDTISSK (12) 4.1 14.82 -10.00 5.10 0.30 5.96 1.02 3.80 0.60
1399.63 545-556 TVMENFVAFVDK (12) 4.2 37.53 6.80 46.67 10.07 17.45 1.98 7.30 0.50
1439.83 336-347 RHPEYAVSVLLR (12) 9.4 32.16 -1.60 4.70 0.50 34.92 15.19 3.60 0.30
1450.60 199-211 CASIQKFGERALK (13) 9.6 23.36 -3.30 9.50 0.10 4.68 1.21 1.10 0.20
1464.73 432-444 VGTRCCTKPESER (13) 8.2 5.56 -14.89 5.40 0.40 18.85 7.83 2.50 0.70
1479.85 397-409 LGEYGFQNALIVR (13) 6.3 35.04 3.80 18.64 1.22 170.71 12.44 41.20 2.60
1496.69 363-375 DDPHACYTSVFDK (13) 4.3 21.87 -10.70 4.10 0.20 6.99 2.39 1.10 0.20
1503.09 525-537 QTALVELLKHKPK (13) 10.5 31.59 -6.80 16.30 5.50 6.84 3.38 2.00 0.30
1511.91 521-533 VPQVSTPTLVEVSR (14) 6.3 27.05 2.90 3.40 0.40 10.36 2.54 2.90 0.00
1519.58 115-127 LKPDPNTLCDEFK (13) 4.4 25.03 -12.80 4.40 0.20 20.55 0.11 3.40 0.80
1546.05 376-388 LKHLVDEPQNLIK (13) 7.5 27.83 -6.50 9.40 1.00 73.85 9.06 2.10 0.20
1567.81 323-335 DAFLGSFLYEYSR (13) 4.2 39.68 -1.10 13.40 0.10 398.24 108.41 3.10 0.40
1578.07 243-256 ECCHGDLLECADDR (14) 3.9 20.09 -8.70 3.10 0.10 5.22 0.57 2.10 0.30
1616.27 94-106 QEPERNECFLSHK (13) 5.6 17.93 -22.40 4.30 0.30 7.40 1.26 2.20 0.90
1630.00 524-537 YNGVFQECCQAEDK (14) 3.9 19.98 -12.80 54.30 10.70 130.77 19.07 1.50 0.30
1640.11 413-427 KVPQVSTPTLVEVSR (15) 9.7 26.99 -1.00 2.30 0.20 8.25 3.68 2.60 0.10
1741.07 363-377 DDPHACYTSVFDKLK (15) 5.5 27.43 -10.80 8.60 1.50 47.23 6.27 1.40 0.30
1755.88 557-573 CCAADDKEACFAVEGPK (17) 4.1 20.98 -2.10 2.70 0.30 7.40 3.62 2.30 0.40
1824.10 484-499 RPCFSALTPDETYVPK (16) 6.2 32.51 -8.60 6.30 0.20 11.16 3.60 3.40 1.00
1851.03 505-520 LFTFHADICTLPDTEK (16) 4.4 35.93 0.70 2.70 0.00 10.08 1.15 1.40 0.30
1956.36 295-312 DAIPEDLPPLTADFAEDK (18) 3.5 36.35 -10.10 3.50 0.40 5.65 0.85 3.30 1.70
2025.48 413-431 KVPQVSTPTLVEVSRSLGK (19) 10.7 32.29 -2.30 2.50 0.20 6.68 1.70 1.00 0.20
2046.53 144-159 RHPYFYAPELLYYANK (16) 8.9 37.08 -13.00 2.30 0.10 25.36 2.56 2.30 0.50
2060.42 410-427 YTRKVPQVSTPTLVEVSR (18) 10.4 29.03 -7.50 2.20 0.20 8.07 4.64 1.20 0.40
2199.68 538-556 ATEEQLKTVMENFVAFVDK (19) 4.1 40.96 -2.70 1.70 0.10 8.84 3.68 1.40 0.30
2414.16 484-504 RPCFSALTPDETYVPKAFDEK (21) 4.5 37.02 -14.90 1.50 0.00 4.30 0.61 1.50 0.40
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Table 3.2 b: Tryptic peptides used in the extraction experiments (anionic NPs) 
 
CxyNP SoaNP
m/z Sequence # Amino acid sequence pI Hb KD K Sd (±) K Sd (±)
604.00 56-60 GITWK (5) 9.7 15.88 -1.40 28.84 7.33 4.80 1.10
634.00 9-13 IFVQK (5) 9.7 14.61 4.10 5.84 2.53 2.70 0.40
678.00 74-79 YIPGTK (6) 9.3 10.36 -3.39 5.62 0.93 1.50 0.10
779.34 80-86 MIFAGIK (7) 9.69 27.42 11.20 9.50 3.20 11.20 3.00
861.00 1-8 GDVEKGKK (8) 9.4 4.53 -15.30 1.55 0.51 0.10 0.00
907.00 80-87 MIFAGIKK (8) 10.1 26.89 7.29 4.12 1.01 0.70 0.10
964.00 92-99 EDLIAYLK (8) 4.2 27.29 1.69 1.62 0.41 2.50 0.40
1169.00 28-38 TGPNLHGLFGR (11) 10.6 25.01 -4.30 63.38 2.10 115.90 25.80
1350.00 89-99 TEREDLIAYLK (11) 4.4 26.99 -6.99 1.94 0.34 1.80 0.20
1470.00 40-53 TGQAPGFTYTDANK (14) 6.2 18.89 -13.80 3.53 2.00 2.10 0.40
1479.19 89-100 TEREDLIAYLKK (12) 6.6 25.42 -10.89 1.84 0.06 2.10 0.30
1495.00 61-72 EETLMEYLENPK (12) 3.8 32.15 -19.40 1.21 0.61 4.80 1.70
1508.95 92-104 EDLIAYLKKATNE (13) 4.43 30.3 0.30 2.36 0.60 3.20 0.40
1598.00 39-53 KTGQAPGFTYTDANK (15) 9.3 17.4 -17.70 14.05 5.02 4.10 0.20
1607.00 87-99 KKTEREDLIAYLK (13) 9.2 25.75 -14.79 1.38 0.21 1.70 0.30
1623.00 61-73 EETLMEYLENPKK (13) 4.2 31.06 -15.50 1.46 0.60 2.90 0.10
1634.85 9-22 IFVQKCAQCHTVEK (14) 8.24 20.23 -8.10 6.41 0.54 272.60 20.80
748.00 133-138 ALELFR (6) 6 26.75 4.19 1.15 0.34 0.40 0.20
941.00 145-153 YKELGFQG (8) 6 20.86 -6.40 2.71 0.53 0.90 0.30
1062.00 43-50 FDKFKHLK (8) 9.7 23.65 -8.99 0.93 0.16 1.20 0.20
1272.00 32-42 LFTGHPETLEK (11) 5.4 23.1 -7.10 2.78 0.59 0.60 0.10
1361.00 46-56 FKHLKTEAEMK (11) 8.5 19.05 -12.30 6.41 1.70 10.30 0.50
1378.80 64-77 HGTVVLTALGGILK (14) 8.76 40.29 16.40 1.30 0.12 12.90 3.00
1502.00 118-132 HPGDFGADAQGAMTK (15) 5.2 20.18 -11.00 2.02 0.16 0.80 0.40
1507.00 63-77 KHGTVVLTALGGILK (15) 10.8 38.79 12.49 1.30 0.06 1.50 0.40
1554.00 140-153 NDIAAKYKELGFQG (14) 7 27.43 -9.20 0.77 0.67 1.50 0.00
1607.00 17-31 VEADIAGHGQEVLIR (15) 4.6 27.29 2.29 0.49 0.10 0.60 0.50
1816.00 1-16 GLSDGEWQQVLNVWGK (16) 5.2 41.59 -9.20 1.99 0.66 1.40 0.90
1853.00 79-95 GHHEAELKPLAQSHATK (17) 7 18.04 -18.39 4.86 1.70 2.20 1.10
1885.02 103-118 YLEFISDAIIHVLHSK (16) 6.5 45.92 9.70 1.44 0.14 49.40 5.50
1982.00 78-95 KGHHEAELKPLAQSHATK (18) 8.5 16.14 -22.29 15.49 1.80 2.60 0.30
2861.36 17-42 VEADIAGHGQEVLIRLFTGHPETLEK (26) 4.7 37.29 -4.80 1.47 0.14 7.50 2.20
3405.33 1-31 GLSDGEWQQVLNVWGKVEADIAGHGQEVLIR (31) 4.2 48.53 -6.89 3.00 0.54 4.90 1.00
648.09 280-284 VYLPR (5) 9.3 15.64 0.60 3.60 0.30 18.98 5.74
780.16 105-110 LYAEER (6) 4.3 8.41 -7.20 0.70 0.20 1.26 0.42
823.14 219-226 VASMASEK (8) 6 6.87 0.70 0.90 0.10 0.10 0.03
887.21 278-284 IKVYLPR (7) 10 22.45 1.20 3.10 0.90 9.33 3.43
906.09  181-187 VYLPRMK (7) 10.5 21.4 -1.40 3.80 0.40 1.47 0.56
976.16 182-189 GLWEKAFK (8) 9.5 26.9 -4.20 1.60 0.30 0.68 0.29
1015.37 277-284 KIKVYLPR (8) 10.9 24.01 -2.70 1.20 0.10 0.80 0.33
1062.58  47-55 DSTRTQINK (9) 9.7 6.45 -16.60 1.00 0.10 29.27 7.82
1080.99  219-228 VASMASEKMK (10) 9.5 13.8 -1.30 3.40 1.80 28.50 6.19
1190.23  360-369 ADHPFLFCIK (10) 7.4 33.56 6.00 1.80 0.60 1.66 0.49
1209.39 190-199 DEDTQAMPFR (10) 3.9 19.14 -14.30 1.80 0.40 1.12 0.29
1345.57 370-381 HIATNAVLFFGR (12) 10.6 36.49 9.40 20.50 4.00 367.00 95.02
1467.19 111-122 YPILPEYLQCVK (12) 6.2 34.8 2.10 1.70 0.40 3.44 1.90
1555.53 187-199 AFKDEDTQAMPFR (13) 4.4 25.23 -13.60 5.30 0.40 3.52 2.92
1581.52 264-276 LTEWTSSNVMEER (13) 4 26.63 -12.50 2.50 0.10 0.81 0.17
1687.71 127-142 GGLEPINFQTAADQAR (16) 4.2 29.68 -8.60 3.40 0.20 2.63 2.22
1709.85 264-277 LTEWTSSNVMEERK (14) 4.5 26.04 -16.40 2.40 0.50 1.40 0.36
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 Table 3.2 b (continued) 
CxyNP SoaNP
m/z Sequence # Amino acid sequence pI Hb KD K Sd (±) K Sd (±)
1774.80 323-339 ISQAVHAAHAEINEAGR (17) 6.5 20.99 -3.90 9.50 1.80 1.50 1.02
1859.91 143-158 ELINSWVESQTNGIIR (16) 4.3 37.43 -4.10 3.90 0.40 14.85 2.94
2250.14 123-142 ELYRGGLEPINFQTAADQAR (20) 4.4 35.58 -14.10 6.70 0.80 3.41 0.73
2281.23 85-104 DILNQITKPNDVYSFSLASR (20) 6.4 39.65 -6.50 2.10 1.00 19.25 8.06
2461.24 159-181 NVLQPSSVDSQTAMVLVNAIVFK (23) 6.3 46.23 15.30 2.40 0.80 12.10 1.80
729.59 1-7 VLSPADK (7) 6.3 10.1 0.00 1.44 0.17 0.13 0.04
766.93 201-207 VKAHGKK (7) 11.1 2.1 -9.30 0.73 0.20 0.72 0.13
819.03 93-99 VDPVNFK (7) 6.3 17.65 -1.30 1.09 0.04 0.54 0.18
931.89 150-158 SAVTALWGK (9) 9.7 23.96 4.90 3.55 0.34 0.50 0.11
951.99 142-149 VHLTPEEK (8) 5.4 13.28 -8.40 1.12 0.11 0.27 0.04
973.93 8-16 TNVKAAWGK (9) 10.8 16.62 -5.50 0.79 0.03 0.65 0.17
1071.03 32-40 MFLSFPTTK (9) 9.7 32.47 3.60 10.24 1.36 0.38 0.13
1087.13 91-99 LRVDPVNFK (9) 9.7 23.68 -2.00 10.78 3.16 0.47 0.04
1126.01 237-245 LHVDPENFR (9) 5.4 21.86 -9.00 1.31 0.18 1.38 0.35
1150.02 274-285 VVAGVANALAHK (12) 9.7 22.62 12.60 6.70 1.36 0.17 0.03
1170.99 1-11 VLSPADKTNVK (11) 9.5 13.39 -3.90 0.65 0.09 0.08 0.00
1252.13 128-139 FLASVSTVLTSK (12) 9.7 29.07 12.90 3.07 0.06 0.92 0.07
1269.04 140-149 YRVHLTPEEK (10) 7.5 17.65 -14.20 1.88 0.33 10.80 8.10
1274.12 172-181 LLVVYPWTQR (10) 9.3 33.32 3.50 78.30 11.74 18.48 3.81
1314.10 159-171 VNVDEVGGEALGR (13) 3.9 21.19 -1.50 0.70 0.11 0.40 0.10
1378.12 262-273 EFTPPVQAAYQK (12) 6.4 21.68 -9.00 1.98 0.21 0.57 0.03
1422.00 224-236 GTFATLSELHCDK (13) 5.4 28.82 -2.00 1.69 0.36 2.39 0.17
1449.15 274-287 VVAGVANALAHKYH (14) 9.3 24.67 8.10 2.60 0.34 1.50 0.12
1529.17 17-31 VGAHAGEYGAEALER (15) 4.5 20.9 -5.50 0.61 0.12 1.31 0.12
1669.37 208-223 VLGAFSDGLAHLDNLK (16) 5.4 36.74 6.60 13.50 3.76 0.49 0.13
1719.77 246-261 LLGNVLVCVLAHHFGK (16) 8.6 39.24 20.30 1.83 0.41 1.08 0.22
1798.36 207-223 KVLGAFSDGLAHLDNLK (17) 7.5 38.19 2.70 2.34 0.04 2.20 0.38
1834.44 41-56 TYFPHFDLSHGSAQVK (16) 7.7 31.7 -7.50 44.63 10.59 7.68 1.44
2060.05  182-200 FFESFGDLSTPDAVMGNPK (19) 3.9 38.05 -4.10 4.74 1.17 1.50 0.40
606.08 1-5 KVFGR (5) 11.7 9.6 -1.80 39.83 4.75 104.45 12.64
874.26 15-21 HGLDNYR (7) 7.5 11.54 -12.60 0.33 0.05 8.89 3.01
936.17 62-68 WWCNDGR (7) 6.2 19.77 -11.20 3.87 1.42 23.08 5.08
1030.53 14-21 RHGLDNYR (8) 9.3 12.35 -17.10 2.19 1.33 3.04 0.62
1045.44 117-125 GTDVQAWIR (9) 6.3 22.94 -2.99 3.62 1.75 2.04 0.93
1268.47 22-33 GYSLGNWVCAAK (12) 8.5 29.56 2.90 52.90 6.22 28.39 3.69
1428.56 34-45 FESNFNTQATNR (12) 6.4 16.15 -16.80 12.99 0.93 1.14 0.69
1450.48 2-14 VFGRCELAAAMKR (13) 9.8 25.08 3.80 0.78 0.35 1.73 0.48
1675.90 98-112 IVSDGNGMNAWVAWR (15) 6.3 32.93 0.00 2.16 0.18 57.84 2.70
1753.95 46-61 NTDGSTDYGILQINSR (16) 4.1 26.96 -14.30 1.95 0.44 1.74 1.30
609.73 500-504 AFDEK (5) 4.2 4.92 -6.30 0.90 0.20 1.40 0.50
649.09 199-204 CASIQK (6) 8.5 4.44 0.60 2.30 0.50 0.70 0.40
658.03 94-98 QEPER (5) 4.3 1.65 -16.60 1.00 0.40 0.80 0.30
688.29 212-217 AWSVAR (6) 10.5 13.09 1.60 8.10 2.90 0.60 0.10
701.08 174-180 GACLLPK (7) 8.5 17.65 6.00 2.20 0.30 1.10 0.20
712.15 5-10 SEIAHR (6) 7.6 4.99 -5.70 0.60 0.20 0.40 0.10
733.06 188-194 VLTSSAR (7) 10.5 7.88 3.00 1.20 0.30 0.70 0.10
752.19 317-322 NYQEAK (6) 6.4 3.1 -13.90 1.10 0.30 1.00 0.30
787.91 233-239 LVTDLTK (7) 6.3 17.02 2.99 1.20 0.40 1.20 0.40
818.03 538-544 ATEEQLK (7) 4.3 6.4 -9.50 1.80 0.40 0.90 0.20
840.89 459-465 LCVLHEK (7) 7.4 15.76 3.70 2.50 0.60 1.10 0.50
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 Table 3.2 b (continued) 
CxyNP SoaNP
m/z Sequence # Amino acid sequence pI Hb KD K Sd (±) K Sd (±)
846.90 218-224 LSQKFPK (7) 10.8 15.69 -7.10 1.30 0.10 1.10 0.50
886.30 107-114 DDSPDLPK (8) 3.8 12.43 -14.60 1.10 0.10 1.30 0.30
922.05 225-232 AEFVEVTK (8) 4.3 20.05 1.40 1.90 0.20 1.20 0.20
927.36 137-143 YLYEIAR (7) 6.5 24.44 -0.50 16.30 0.60 0.30 0.10
974.34 13-20 DLGEEHFK (8) 4.4 16.23 -11.40 1.30 0.20 0.60 0.00
977.36 99-106 NECFLSHK (8) 7.4 16.6 -5.80 2.20 0.40 1.00 0.00
1011.11 389-396 QNCDQFEK (8) 4.2 7.55 -16.09 2.50 0.50 1.60 0.20
1014.57 525-533 QTALVELLK (9) 6.3 32.23 5.80 3.40 1.20 0.80 0.20
1050.39 564-573 EACFAVEGPK (10) 4.4 19.69 0.20 4.60 1.60 1.60 0.50
1084.59 137-144 YLYEIARR (8) 9.2 24.29 -5.00 1.30 0.30 1.60 0.40
1144.68 212-221 AWSVARLSQK (10) 11.7 21.64 -2.80 1.40 0.10 1.10 0.20
1163.47 42-51 LVNELTEFAK (10) 4.3 28.48 1.30 7.40 1.70 1.00 0.10
1197.56 313-322 DVCKNYQEAK (10) 6.3 6.24 -14.60 1.70 0.20 1.00 0.10
1202.63 195-204 QRLRCASIQK (10) 11.5 11.9 -8.10 2.00 0.30 1.00 0.10
1249.39 11-20 FKDLGEEHFK (10) 5.5 22.54 -12.50 3.20 1.00 1.30 0.40
1283.67 337-347 HPEYAVSVLLR (11) 7.5 32.31 2.89 9.80 1.00 2.20 0.50
1293.68 222-232 FPKAEFVEVTK (11) 6.4 27.48 -1.30 2.00 0.20 1.50 0.20
1305.61 378-388 HLVDEPQNLIK (11) 5.5 25.69 -6.40 9.00 2.10 1.10 0.30
1345.51 174-185 GACLLPKIETMR (12) 6.2 28.89 3.70 2.00 0.30 0.90 0.10
1361.09 65-76 SLHTLFGDELCK (12) 5.5 30.18 0.70 2.00 0.40 1.10 0.20
1386.31 262-273 YICDNQDTISSK (12) 4.1 14.82 -10.00 4.00 1.10 1.00 0.10
1399.63 545-556 TVMENFVAFVDK (12) 4.2 37.53 6.80 5.20 1.30 0.60 0.10
1439.83 336-347 RHPEYAVSVLLR (12) 9.4 32.16 -1.60 8.00 0.60 7.50 2.50
1450.60 199-211 CASIQKFGERALK (13) 9.6 23.36 -3.30 1.50 0.30 1.20 0.10
1464.73 432-444 VGTRCCTKPESER (13) 8.2 5.56 -14.89 2.00 0.30 1.50 0.20
1479.85 397-409 LGEYGFQNALIVR (13) 6.3 35.04 3.80 25.80 4.00 2.40 0.50
1496.69 363-375 DDPHACYTSVFDK (13) 4.3 21.87 -10.70 2.80 0.60 1.10 0.10
1503.09 525-537 QTALVELLKHKPK (13) 10.5 31.59 -6.80 2.30 0.30 1.40 0.40
1511.91 521-533 VPQVSTPTLVEVSR (14) 6.3 27.05 2.90 14.20 5.90 0.60 0.10
1519.58 115-127 LKPDPNTLCDEFK (13) 4.4 25.03 -12.80 2.90 0.60 1.30 0.40
1546.05 376-388 LKHLVDEPQNLIK (13) 7.5 27.83 -6.50 1.50 0.30 0.80 0.20
1567.81 323-335 DAFLGSFLYEYSR (13) 4.2 39.68 -1.10 7.00 1.20 9.32 1.09
1578.07 243-256 ECCHGDLLECADDR (14) 3.9 20.09 -8.70 2.20 0.50 2.60 0.10
1616.27 94-106 QEPERNECFLSHK (13) 5.6 17.93 -22.40 2.60 0.70 1.20 0.10
1630.00 524-537 YNGVFQECCQAEDK (14) 3.9 19.98 -12.80 3.40 0.50 1.10 0.20
1640.11 413-427 KVPQVSTPTLVEVSR (15) 9.7 26.99 -1.00 85.20 10.10 0.60 0.10
1741.07 363-377 DDPHACYTSVFDKLK (15) 5.5 27.43 -10.80 1.40 0.20 1.20 0.20
1755.88 557-573 CCAADDKEACFAVEGPK (17) 4.1 20.98 -2.10 3.20 0.20 1.80 0.20
1824.10 484-499 RPCFSALTPDETYVPK (16) 6.2 32.51 -8.60 3.70 0.50 4.40 0.30
1851.03 505-520 LFTFHADICTLPDTEK (16) 4.4 35.93 0.70 1.80 0.40 1.30 0.30
1956.36 295-312 DAIPEDLPPLTADFAEDK (18) 3.5 36.35 -10.10 8.50 1.60 0.80 0.10
2025.48 413-431 KVPQVSTPTLVEVSRSLGK (19) 10.7 32.29 -2.30 2.20 0.30 1.10 0.10
2046.53 144-159 RHPYFYAPELLYYANK (16) 8.9 37.08 -13.00 4.60 1.40 69.57 2.25
2060.42 410-427 YTRKVPQVSTPTLVEVSR (18) 10.4 29.03 -7.50 2.50 0.60 1.30 0.60
2199.68 538-556 ATEEQLKTVMENFVAFVDK (19) 4.1 40.96 -2.70 2.30 0.50 1.10 0.20
2414.16 484-504 RPCFSALTPDETYVPKAFDEK (21) 4.5 37.02 -14.90 3.30 0.60 1.50 0.20
 
Hb is hydrophobicity calculated using the SSR software and KD is hydrophobicity 
calculated using the Kyte-Doolittle scale (peptides that have Hb values above zero are 
hydrophobic while peptides that have Hb values below zero are hydrophilic).  
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Table 3.3: Summary (peptides used) 
 
NPs # peptides pI<pH
 
pI>pH pI = pH 
TmaNP (I) 146 82 61 3 
TmaNP(II) 146 82 61 3 
LysNP 146 82 61 3 
SoaNP 146 82 61 3 
CxyNP 146 99 46 1 
 
carried out at a solution pH of 8.6. As a result, 99 of the peptides are negatively-
charged, 46 are positively charged, and one peptide is neutral (table 3.3).  
Due to the many potential factors (e.g. charge, hydrophobicity, H-bonding capability, 
peptide amino acid content, etc.) that can contribute to the extractions process, we have 
used multiple least squares regressions (MLSR) to develop a model to predict the K 
values using peptide pI and hydrophobicity (Hb). Two scales were used to calculate the 
hydrophobicity values of the peptides. The Hb values used in the model were obtained 
using the Shaun D. Black (SDB) scale, 58 which is based on a modification of 
hydrophobic fragmental constant approach of Rekker. 59 Rekker studied the phase 
partition behavior of a very large database of compounds and by means of multiple 
regression analysis he obtained polarity constants for a large number of molecular 
fragments. 
Chemically, these hydrophobic fragmental constants can be combined to assess 
with good accuracy the polarity of essentially any compound. The Kyte-Doolitle (KD) 
scale 61 was employed to assist the general data interpretation. This scale used the 
water-vapor transfer free energies plus interior-exterior distribution of amino acid side 
chains in assessing the hydropathy values of the amino acid residues. In table 3.2, 
peptides that have negative KD values are hydrophilic while those that have positive 
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values are hydrophobic.  
As indicated above, for a typical extraction experiment, 1 µM of digest is 
extracted with 10 µM NP in 300 µL of solution. The digest-NP mixture is then 
concentrated to 10 µL (residue). This is followed by removal of the trapped peptides 
from the NPs with 5 µL of the releasing agent, so that the extracted peptides are in a 
final volume of 15 µL. The residue is thus 20 times concentrated assuming complete 
extraction. 5 µL of the MALDI matrix is then added to 1 µL of both the residue and the 
supernatant for the MALDI-TOF MS analysis. Given the concentration factor, we have 
arbitrarily chosen a K value of 20 as the cutoff for describing whether a peptide is 
extracted or not.  In effect, this cutoff value corresponds to a peptide equally 
partitioning between the NP and the solution. Based on this threshold value, TmaNP (I), 
TmaNP (II) and LysNP extracted only 14.38%, 20.55% and 9.59% of the peptides, 
respectively, while CxyNP and SoaNP extracted only 6.16 % and 7.53% of the 
peptides, respectively (Table 3.4). As a result, peptides with K values below the cutoff 
value (K< 20) were assigned a value of K = 0 and those with 20≥ K<30 were assigned 
K=1 for the MLSR model.  
Table 3.4: Extracted peptides 
 
NPs # peptides K>20 % (K>20) 
TmaNP (I) 146 21 14.38 
TmaNP(II) 146 30 20.55 
LysNP 146 14 9.59 
SoaNP 146 11 7.53 
CxyNP 146 9 6.16 
 
K> 20 is the threshold value for whether a peptide is extracted or not. 
 
To explain the large number of peptides that were not extracted (K<20) by the 
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NPs, we estimated the number of total binding sites present on a collection of NPs in 
the following way.  We estimate that one NP can bind and accommodate up to 5 peptide 
molecules on its surface (i.e. a nanoparticle with a diameter of 3 nm has a total surface 
area of 28.26 nm2. An average peptide with 13 amino acids has a surface area of 22.13 
nm2, assuming an average amino acid surface area of 1.70 nm2. 62 By further assuming 
that about one quarter of the total surface area of a given peptide will be utilized in 
binding to the NP, we estimate that a single NP can bind a maximum of five peptides).  
Thus, the effective concentration of NP binding sites is approximately 50 µM when the 
NP solution concentration is 10 µM. After digestion the total concentration of peptides 
is between 10 and 50 µM, depending on the number of peptide fragments produced 
from a protein whose concentration began at 1 µM.  Upon considering the relative 
concentrations of the peptides and the NP binding sites, it becomes clear why the 
overall number of peptides that are extracted is relatively low. Significant competition 
for the binding sites exists, and only those with high affinities or significantly higher 
concentrations were efficiently extracted.  
Also, from figure 3.2 – 3.6, almost all of the peptides that were extracted with 
K>20 have at least one aromatic amino acid residue in its sequence, and it is likely that 
after binding to the NPs, the bulky side chains of these peptides might have hindered 
the other peptides from binding to the NPS. It is also possible that some of the peptides 
were lost when they were being removed from the NPs. Also, the high concentration of 
aqueous NaCN (65 mM) required for the dissolution of the core of TmaNP (I) might 
have acted to suppress the MALDI ion signals for the peptides extracted with this NP.  
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Figure 3.2: Extractions with TmaNP (I) 
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 Figure 3.3: Extractions with TmaNP (II)                              
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Figure 3.4: Extractions with LysNP 
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Figure 3.5: Extractions with CxyNP 
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Figure 3.6: Extractions with SoaNP 
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After performing the MLSR analysis using a K value of 20 as a cutoff, it 
becomes clear that pI is the most important factor affecting extraction efficiency. This is 
further supported by the observation that less than 50% of the total peptides extracted 
by the NPs are hydeophobic (i.e. have positive KD values), table 3.5. A summary of the 
MLSR analysis, displaying the regression coefficients, the intercepts and the 
coefficients of the model equation for the various NPs is shown in table 3.6.  
 
Table 3.5: Percent hydrophobicity (total) 
 
NPs K>20 Hb %Hb K>100 %Hb(K>100 
TmaNP (I) 21 5 23.81 1 0 
TmaNP(II) 30 7 23.33 11 18.2 
LysNP 14 3 21.43 3 0 
SoaNP 11 4 36.36 0 0 
CxyNP 9 4 44.44 4 25 
 
The Hb values used in this tablel were computed from the KD scale 
 
 
Table 3.6: Summary of model* parameters 
 
NP a b1 b2 R2 
TmaNP (I) 13.905 -2.355 1.418 0.095
TmaNP (II) 39.793 -5.823 3.421 0.085
LysNP 16.215 -2.611 1.366 0.097
SoaNP -26.564 3.473 1.589 0.046
CxyNP -13.12 1.288 1.109 0.093
     
* The model is based on the equation K = b1(pI) + b2(Hb) + a; where K is the extraction 
capacity, a is the intercept and b1 and b2 are the coefficients of the peptide isoelectric point (pI) 
and hydrophobicity respectively. The Hb values used in the model was computed from the SDB 
scale 
 
The model revealed that for all the extractions involving the three positively-charged 
NPs, peptide pI correlates negatively with K, while for the extractions involving the 
negatively-charged NPs peptide pI correlates positively with K.  
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This observation is in agreement with the K vs. pI plots shown in figure 1 and indicates 
that the cationic and anionic NP systems exhibit opposite selectivity towards the 
peptides, which was also observed in chapter 1 for a more limited set of peptides. In 
other words, the cationic NPs showed a high preference for the peptides that have low 
pI values while the anionic NPs showed a preference for the peptides that have high pI 
values. For example, TmaNP (I) extracted 25.61% (21 out of 82) of the peptides that 
have low pI (i.e. below 7.4) values. Likewise, TmaNP (II) and LysNP respectively 
extracted 29.27% (24 out of 82) and 15.85% (13 out of 82) of the low pI peptides. 
Conversely, SoaNP and CxyNP respectively extracted 13.11% (8 out of 61) and 13.04% 
(6 out of 46) of the peptides that have high pI values (table 3.7). The cationic NPs 
extracted the peptides that have low pI values because these peptides were negatively 
charged at the solution pH for the extraction. In other words, the low pI (negatively-
charged) peptides experienced strong electrostatic interactions with the cationic NPs. 
On the contrary, the peptides that have high pI values were extracted by the anionic NPs 
because they were positively charged at the solution pH for the extraction.  
 
Table 3.7: Percent extractions (high and low pI peptides) 
 
    
K>20 
LpI %LpI HpI %HpI 
 NPs  pI<pH  pI>pH (K>20) (K>20) (K>20) (K>20) 
TmaNP (I) 82 61 21 21 25.61 0 0 
TmaNP(II) 82 61 30 24 29.27 6 9.84 
LysNP 82 61 14 14 15.85 1 1.64 
SoaNP 82 61 11 3 3.66 8 13.11 
CxyNP 99 46 9 3 3.03 6 13.04 
 
Where %HpI and %LpI are respectively the percentages of the peptides extracted, that have 
high or low pI values. 
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The extraction of the peptides was accompanied by high concentration factors 
such that some of the NPs extracted peptides with K values greater than100 (that is 
more than five times the expected concentration factor). For example, TmaNP (II) gave 
K values greater than 100 for 11 negatively-charged peptides, and SoaNPs gave K 
values greater than 100 for 4 positively-charged peptides (table 3.5). One common thing 
about the peptides that were extracted with K>100 is that all of them are polar in nature, 
for instance, the KD scale predicted that only 18.8% (2 out of 11) of the negatively 
charged (pI < pH) peptides that were extracted by TmaNP (II), and only 25% (1 out of 
4) of positively charged (pI > pH) peptides extracted by SoaNP are hydrophobic in 
nature (table 3.5), which suggests that the extraction of these peptides might have been 
driven mainly by complementary electrostatic interactions.  
 It is also important to note that both the cationic and anionic NPs extracted 
peptides of the same polarity.  In other words, the cationic NPs extracted peptides that 
are positively-charged and the anionic NPs extracted peptides that are negatively-
charged under the solution conditions for the extraction. For example, CxyNP and 
SoaNP respectively extracted 3.03% (3 out of 99) and 3.66% (3 out of 82) negatively-
charged peptides, and while TmaNP (I) did not extract any of the positively-charged 
peptides, TmaNP (II) and LysNP respectively extracted 9.84% (6 out of 61) and 1.64% 
(1 out of 61) positively-charged peptides. Again, using the KD scale, we found that 
66.67% (2 out of 3) of the negatively charged peptides that were extracted by CxyNP 
and SoaNP, 33.33% (2 out of 6) of the positively-charged peptides extracted by TmaNP 
(II), and none (one out of one) of the positively charged peptide that was extracted by 
LysNP are hydrophobic in nature (table 3.8). 
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Table 3.8: Percent hydrophobicity* of the extracted peptides. 
  
NPs 
# peptides 
K>20 
#  peptides
pI<pH 
# peptides 
pI>pH 
% Hb 
(pI<pH)
% Hb 
(pI>pH) 
TmaNP (I) 21 21 0 23.81 0.00 
TmaNP(II) 30 24 6 20.83 33.33 
LysNP 14 13 1 23.08 0.00 
SoaNP 11 3 8 66.67 25.00 
CxyNP 9 3 6 66.67 33.33 
 
*Estimations were done using the KD scale 
 
Thus, even though this involves a small set of peptides, it seems again, that 
complementary electrostatic interactions dominated their extraction. 
The MLSR data further predicted that hydrophobicity correlates positively with 
K for all the NP systems. This correlation is consistent with the presence of alkane 
groups in the shells of all the NPs (table 3.1). Thus, it is not surprising that peptide 
hydrophobicity is an important factor that controls extraction efficiency in addition to 
complementary electrostatic interactions. However, complementary electrostatic 
interactions tend to dominate the extraction process because the peptides that were 
extracted by the NP systems appear to have greater effective polar character (table 3.8).  
Also besides their abilities to interact with the peptides via hydrophobic and 
electrostatic interactions, the NP systems, especially LysNP, SoaNP and CxyNP have 
hydrogen bonding capabilities too, and can thus hydrogen bond with the peptides. 
Hydrogen bonding is not accounted for in the model, however, which in part may 
account for the low R2 values yielded by the model. For the K values obtained for 
TmaNP (I), for example, the model gave an R2 value 0.095 (table 3.6), which means 
that complementary electrostatic and hydrophobic interactions could account for only 
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9.5% of the variances in the K values, for the extractions with this NP. Another factor 
that may account for the low R2 value is the method we employed to remove the trapped 
peptides from the NPs before the MALDI-TOF analysis. We suspect that the releasing 
agents used did not remove all the trapped peptides with the same efficiency, and this 
could bias the K values for some NPs.   
Another interesting observation is that, in general, the cationic NPs extracted a 
lower percentage of peptides than the anionic NPs. The reasons for this are not clear.  
Interestingly, though, is the fact that SoaNP, while extracting only only 8% of the 
peptides, together with TmaNP (II) gave the highest K values. These results suggest 
that SoaNP may be highly selective, and future experiments will attempt to identify the 
nature of this selectivity.  
 
3.3 CONCLUSION 
In summary, we have created and screened five different NP systems with 
cationic or anionic functional groups against a test library of 146 peptides to learn about 
the factors that affect the extraction selectivity of the NPs. MLSR shows that even 
though complementary electrostatic interactions dominate the extraction process, 
hydrophobic-hydrophobic interactions are also important and that the two parameters 
together account for an average of 8.3% of the variance in K for all the NPs.  
The cationic or anionic NPs can selectively extract negatively- or positively-
charged peptides, respectively, with efficiencies that depend upon the peptides’ pI 
values and the solution pH. That is, as we have suggested before [chapter 1], these NPs 
can still be used to fractionate digests of new proteins for example, and their ability to 
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discriminate between peptides with low- and high-pI can be used as a constraint during 
database searches for protein identification.  
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CHAPTER 4 
USE OF FUNCTIONALIZED NANOPARTICLES AS SELECTIVE 
EXTRACTION AND CONCENTRATION AGENTS FOR MICROCYSTINS 
Due to their small size dimensions, nanoparticles (NPs) possess large surface 
area-to-volume ratio and have been used by many researchers, including our group to 
trap and concentrate biological molecules from dilute solutions [chapters 1] prior to 
analysis. Despite their positive attributes, NPs have not been used to extract and 
concentrate MC-LR from dilute solutions prior to their detection. Microcystins are 
relatively polar molecules due to the presence of free carboxylic acids in their structures 
and the frequent presence of arginines at positions 2 and 4 [chapter 1]. Thus, NPs 
terminated with cationic or anionic ligands can be designed to target the D –MeAsp and 
D –Glu groups at positions 3 and 6 or the side chain of arginine, respectively.  In this 
chapter, we examined the feasibility of using cationic mixed monolayer protected gold 
NPs as efficient extraction and concentration agents in conjunction MALDI-TOF MS to 
detect MC-LR from dilute solutions. 
 
4.1 EXPERIMENTAL 
4.1.1 Materials and Reagents  
Microcystin LR (MC-LR), α-cyano-4-hydroxycinnamic acid (α-CHCA) and all 
chemicals for the NP fabrication were purchased from Aldrich. Tris-(hydroxymethyl) 
aminomethane (Tris) and tris-(hydroxymethyl) aminomethane hydrochloride (Tris-HCl) 
were purchased from EM science. The water used in all the experiments was obtained 
from a Milli-Q water purification system (Millipore, Bedford, MA, USA). The 
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Centricon filters and centrifuge tubes were purchased from Millipore Corporation.  
 
4.1.2 Sample Extraction with NP’s 
The fabrication and characterization of the gold NP (TmaNP (I)) system used in 
this work have been described elsewhere [chapter 1]. A stock solution of MC-LR was 
prepared in 50/50 deionized water/methanol. The stock solution was diluted to working 
concentrations in a 25 mM Tris/Tris-HCl buffer at the desired pH (8.6). To extract the 
toxin from solutions, different amounts of NP solutions were added to different amounts 
of the toxin in a 10000 MW Centricon cut-off filter and the mixture was vortexed for 10 
minutes. The toxin-bound NPs were aggregated and separated from the reaction 
supernatant by centrifugation in an Allegra™ X-22R centrifuge (Beckman CoulterTM). 
MALDI-TOF MS analysis was then performed on the residue and the supernatant after 
the gold NPs had been removed from the residue. A solution mixture of trifluoroacetic 
acid, acetonitrile and water (5%TFA/20%ACN /75%H2O) was used as the releasing 
agent.  
4.1.3 MALDI-TOF-MS  
All mass spectra were acquired in positive ion mode using an REFLEX III 
(Bruker Daltonics) in reflectron mode. The laser fluence was adjusted for optimum 
resolution and peak intensity in the 900 - 1200 m/z range. each mass spectrum was 
acquired by accumulation of 100 laser shots. The matrix solution consisted of α-CHCA 
saturated in 70%ACN:30%H2O, 0.1% TFA (v/v). The dried-droplet method was used 
for all the samples. Typically, 1 µl of the residue or supernatant was mixed with 5 µl of 
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the matrix solution, and an aliquot (1 µl) of this mixture was applied to the stainless 
steel probe and allowed to air dry before the MALDI-TOF-MS measurements. 
 
4.2 RESULTS AND DISCUSSION 
In chapter 1 we found that cationic and anionic mixed monolayer protected gold 
clusters (MMPCs) were remarkably good extracting agents for peptides. We attributed 
the high extraction capacities of the NPs for the peptides to the high surface area-to-
volume ratio of the NPs, which allows for efficient capture of the target peptides into a 
limited analysis volume, thereby effecting sample preconcentration.   
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Figure 4.1: MALDI mass spectrum of a 80 nM solution of microcystins-LR ([M+H]+ = m/z 
995.17) after extraction and concentration with TmaNP (I). The extraction was carried out at a 
pH of 8.6 
 
Figure 4.1 shows the results of the analysis of a solution of 80 nM MC-LR after 
extraction with a 5 µM solution of TmaNP (I) in 500 µL at a pH of 8.6.  Virtually no 
identifiable ion signal is observed for MC-LR when solution of the peptide is analyzed 
directly (not shown). However, upon extraction and concentration of the same sample 
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solution with TmaNP (I), the protonated species of MC-LR is easily observable in the 
mass spectrum (Fig 4.1). After extraction, the mixture was concentrated to a final 
volume of 5 µL, and 5 µL of the releasing agent was added to remove the gold NP prior 
to MALDI-TOF MS analysis, resulting in an expected concentration factor of 33. 
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Figure 4.2: MALDI mass spectra of a 0.8 nM solution of microcystin-LR ([M+H]+ = m/z 
995.17) after extraction and concentration with TmaNP (I). The extraction was carried out at a 
pH of 8.6 
 
Figure 4.2 further displays the results of extraction and concentration of 0.8 nM 
of MC-LR using a 2.5 µM solution of TmaNP (I) in 2 mL at pH 8.6.  The mixture was 
concentrated to a final volume of ~ 1 µL. 10 µL of the releasing agent was used to rinse 
the peptides off the NPs before the MALDI-TOF MS analysis, yielding a concentration 
factor of ~ 182. As might be expected, no identifiable protonated species is observed for 
the toxin before extraction/concentration (data not shown). The protonated species can, 
however, be observed after treatment with the gold NP. In this experiment, the starting 
concentration (0.796 µg/L) is below the WHO provisional guideline of 1 µg/L. Thus, 
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even though this experiment was performed by spiking deionized water with the toxin, 
we suspect that this NP could be used to assist the detection of relevant concentrations 
of the toxin in more complex environments, like from sea water and lake water samples.   
 
4.3 CONCLUSION 
Following the method described in chapter 1, we have used a cationic MMPC 
(TmaNP (I)) in combination with MALDI-TOF MS to detect MC-LR from very dilute 
solutions. Even though this NP may not be really specific for the toxin, we have taken 
advantage of its high extraction capacity to extract and concentrate MC-LR at a 
concentration (0.796 µg/L) below the WHO provisional guideline of 1 µg/L. This 
MMPC, therefore, has the potential of serving as extraction and concentrating agents 
for microcystins from complex environmental sample like lake and sea water, prior to 
their detections by other techniques. 
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                                               CHAPTER 5 
FUTURE DIRECTIONS 
So far, we have developed and tested a general peptides extraction protocol 
using functionalized gold NPs, and we have also screen several NPs against a test 
library of 146 peptides in order to understand the factors that dictate their extraction 
selectivity. Yet much more remains to be done. For example, we do not completely 
understand the factors that govern the selectivity of the NPs for the peptides as about 
80% of the peptides were not extracted. We therefore recommend that the peptide-NP 
ratio for the extraction of digest should be further investigated. For example, the current 
peptide concentration of 1µL can be halved to see if at that concentration, the extraction 
capacity of the NPs can be improved for the digest. The size of the test peptide library 
should also be increased, as this will add more features to the pI vs. K plots and thus 
enrich our understanding of the extraction selectivity of the NPs. Also, future 
experiments should be designed such that only one batch of NPs and protein digests are 
used for all the extractions. It is expected that this would minimize the variance in K for 
peptides from the same protein.  
We have also exploited the large extraction capacities associated with 
extractions with these NPs to extract and concentrate microcystin-LR at levels below 
the WHO provisional guideline of 1µg/L. Even though the NP used for this experiment 
is not really specific for the target, we recommend that the selectivity of this NP for 
MC-LR should be tested by applying it to MC-LR in more complex environments like 
lake water and sea water. 
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5.1 COVALENT CAPTURE OF MICROCYSTINS 
Also, as indicated earlier, microcystins are known to bind covalently to several 
serine/threonine protein phosphatases including protein phosphatase 1 (PP1) and 
protein phophatase 2A (PP2A) via a Michael addition reaction and thus inhibit their 
functions [chapter 1]. We will exploit this very reaction to capture the toxins covalently 
from very dilute solutions. A Diels-Alder reaction will also be investigated as an 
alternative means to capture and extract the toxin covalently from very dilute solutions.   
 
 
Figure 5.1: Reaction scheme for microcystin and the hydrazine functionalized NP 
 
For the covalent capture via a nucleophilic Michael addition reaction, tap water 
and sea water will be spiked with the toxins, and NPs that are functionalized with 
nucleophilic Michael donors (i.e. hydrazine) will be used to extract and concentrate the 
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toxins covalently. These NP systems are expected to bind covalently to the α–β 
unsaturated groups of the N-methyldehydroalanine (Mdha) group of the toxins (fig. 5.1) 
in a 1, 4-conjugated addition reaction, which is similar to the way that the toxins inhibit 
protein phosphatases. It is expected that the ionic functional groups on the NPs will 
guide microcystins to the reaction site. Aggregation and separation of the toxin-NP 
conjugate will be done following the general protocol described above, and the extract 
will be detected using MALDI-TOF MS. 
 
Figure 5.2: Reaction scheme for microcystin and the 1, 2, 4-triazoline-3, 5-dione 
functionalized NP 
 
For the covalent capture via the Diels-Alder reaction, NPs bearing ligands that 
are terminated with 1, 2, 4-triazoline-3, 5-dione will be created and applied to the toxins 
in a manner similar to the Michael extraction. This NP system is expected to bind 
covalently with the conjugated diene in the side group of the “Adda” amino acid in a [2 
+ 4] Diels-Alder reaction (fig. 5.2). The 1, 2, 4-triazoline-3, 5-dione moiety is one of 
the most reactive dienophiles and has recently been attached to a fluorescent dye to 
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successfully detect microcystins 63. In our approach, however, the target-NP conjugate 
will be detected with MALDI-TOF-MS, after extraction and concentration. Unlike the 
non-covalent approach, the binding between the NPs and the toxins will not be lost 
during the aggregation and separation protocol. Furthermore, covalent capture is more 
specific and is thus expected to give even more efficient and highly selective extraction. 
Despite the advantages associated with covalent capture, the approach is also 
expected to pose problems when it comes to releasing the captured toxins for MALDI-
TOF analysis. To overcome this problem, aqueous sodium cyanide will be used to 
decompose the gold core of the NP, and the captured toxin will be detected as an dduct. 
Another approach to overcome this problem is the use of acid-labile linkers. In this 
case, the hydrazine and the 1, 2, 4-triazoline-3, 5-dione functionalities of the two NPs 
will be attached to the gold clusters of the NP through an acid cleavable ligand. Such a 
linker will contain an ester unit, which can be easily cleaved at acidic pH prior to the 
MS analysis. In the case of very complex mixtures, the MS analysis could be simplified 
by using linkers that are synthesized with isotope labels (e.g. 79Br and 81Br) that provide 
a distinct signature during MS analysis. Because most MALDI matrices are acidic, it is 
expected that the linker will be cleaved upon mixing with the MALDI matrix. 
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